Literature DB >> 11464216

The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway.

R H Decker1, Y Dai, S Grant.   

Abstract

Flavopiridol (FP), an inhibitor of cyclin dependent kinases 1, 2 and 4, potently induced apoptosis in U937 human monoblastic leukemia cells. This process was accompanied by characteristic morphological changes, inner mitochondrial membrane permeability transition, release of cytochrome c, processing of procaspases, and generation of reactive oxygen species. Significantly, the general caspase inhibitor Boc-FMK did not block the release of cytochrome c, whereas it did block cleavage of BID and the loss of Deltapsi(m). Neither FP-induced apoptosis nor cytochrome c release was inhibited by the pharmacological caspase-8 inhibitor IETD-FMK or endogenous expression of viral caspase-8 inhibitor CrmA. Finally, FP-mediated apoptosis, but not cytochrome c release, was partially blocked by the free radical scavenger LNAC. Collectively, these findings indicate that FP induces apoptosis in U937 cells via the release of cytochrome c from the mitochondria and independently of activation of procaspase-8.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11464216     DOI: 10.1038/sj.cdd.4400868

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  22 in total

1.  Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Authors:  Judith E Karp; Elizabeth Garrett-Mayer; Elihu H Estey; Michelle A Rudek; B Douglas Smith; Jacqueline M Greer; D Michelle Drye; Karen Mackey; Kathleen Shannon Dorcy; Steven D Gore; Mark J Levis; Michael A McDevitt; Hetty E Carraway; Keith W Pratz; Douglas E Gladstone; Margaret M Showel; Megan Othus; L Austin Doyle; John J Wright; John M Pagel
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

2.  Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.

Authors:  Judith E Karp; B Douglas Smith; Linda S Resar; Jacqueline M Greer; Amanda Blackford; Ming Zhao; Dwella Moton-Nelson; Katrina Alino; Mark J Levis; Steven D Gore; Biju Joseph; Hetty Carraway; Michael A McDevitt; Lorena Bagain; Karen Mackey; Janet Briel; L Austin Doyle; John J Wright; Michelle A Rudek
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

Review 3.  Acute myeloid leukaemia: optimal management and recent developments.

Authors:  Luis Villela; Javier Bolaños-Meade
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

4.  Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Authors:  Judith E Karp; Amanda Blackford; B Douglas Smith; Katrina Alino; Amy Hatfield Seung; Javier Bolaños-Meade; Jacqueline M Greer; Hetty E Carraway; Steven D Gore; Richard J Jones; Mark J Levis; Michael A McDevitt; L Austin Doyle; John J Wright
Journal:  Leuk Res       Date:  2009-12-04       Impact factor: 3.156

Review 5.  Exploiting cellular pathways to develop new treatment strategies for AML.

Authors:  Amir T Fathi; Steven Grant; Judith E Karp
Journal:  Cancer Treat Rev       Date:  2010-01-06       Impact factor: 12.111

6.  Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

Authors:  Mitch A Phelps; Thomas S Lin; Amy J Johnson; Eunju Hurh; Darlene M Rozewski; Katherine L Farley; Di Wu; Kristie A Blum; Beth Fischer; Sarah M Mitchell; Mollie E Moran; Michelle Brooker-McEldowney; Nyla A Heerema; David Jarjoura; Larry J Schaaf; John C Byrd; Michael R Grever; James T Dalton
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

7.  Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.

Authors:  Wenjun Ni; Jia Ji; Zunyan Dai; Audrey Papp; Amy J Johnson; Sunjoo Ahn; Katherine L Farley; Thomas S Lin; James T Dalton; Xiaobai Li; David Jarjoura; John C Byrd; Wolfgang Sadee; Michael R Grever; Mitch A Phelps
Journal:  PLoS One       Date:  2010-11-01       Impact factor: 3.240

Review 8.  Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents.

Authors:  Yun Dai; Steven Grant
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

Review 9.  New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.

Authors:  Amir T Fathi; Judith E Karp
Journal:  Curr Oncol Rep       Date:  2009-09       Impact factor: 5.075

10.  Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.

Authors:  Syed-Rehan A Hussain; David M Lucas; Amy J Johnson; Thomas S Lin; Alan P Bakaletz; Vinh X Dang; Serge Viatchenko-Karpinski; Amy S Ruppert; John C Byrd; Periannan Kuppusamy; Elliott D Crouser; Michael R Grever
Journal:  Blood       Date:  2008-01-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.